• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [83 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2024 Basque Office for Health Technology Assessment (OSTEBA) [Use of self-sampling for the detection of human papillomavirus in cervical cancer screening]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2021 Malaysian Health Technology Assessment (MaHTAS) HPV vaccine - an update
2020 Institute for Clinical Effectiveness and Health Policy (IECS) [Human papilloma virus (HPV) vaccine in patients with HPV lesions or infection]
2020 Canary Health Service [HPV vaccination in adolescent boys: cost-effectiveness and budget impact]
2019 Canadian Agency for Drugs and Technologies in Health (CADTH) HPV testing for primary cervical cancer screening: a health technology assessment
2019 Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: pharmacological treatment of sexually transmitted and blood-borne infections ─ external condylomas (anogenital warts)]
2019 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria
2019 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) Medicinsk teknologivurdering (MTV) af HPV vaccination til drenge
2019 Belgian Health Care Knowledge Centre (KCE) Cost-effectiveness analysis of HPV vaccination of boys in Belgium
2018 NIHR Health Technology Assessment programme Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation
2018 Health Information and Quality Authority (HIQA) Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys
2017 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: comparison of cervical cancer screening strategies involving the human papillomavirus screening test (HPV test) or gynecological cytology (Pap test)]
2017 Health Information and Quality Authority (HIQA) Health technology assessment of human papillomavirus testing as the primary screening method for prevention of cervical cancer
2017 Adelaide Health Technology Assessment (AHTA) Serious adverse events associated with HPV vaccination
2016 HAYES, Inc. 5-aminolevulinic acid photodynamic therapy versus carbon dioxide laser ablation for the treatment of condylomata acuminata
2016 HAYES, Inc. Carbon dioxide (CO2) laser ablation versus other surgical treatment of condylomata acuminata
2016 Basque Office for Health Technology Assessment (OSTEBA) [Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation]
2016 NIHR Health Technology Assessment programme A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC)
2015 Norwegian Institute of Public Health (NIPH) Cost-effectiveness of HPV-vaccination of boys aged 12 in a Norwegian setting
2015 Belgian Health Care Knowledge Centre (KCE) Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) HPV OncoTect E6, E7 mRNA assay to guide colposcopy referral in cervical cancer screening
2014 National Evidence-based Healthcare Collaborating Agency (NECA) [Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in South Korea]
2014 Medical Services Advisory Committee (MSAC) National Cervical Screening Program renewal
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benefit assessment of an HPV test in primary screening for cervical cancer - Rapid report]
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) HPV OncoTect™ E6, E7 mRNA assay to guide colposcopy referral in cervical cancer screening
2014 NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds
2014 NIHR Health Technology Assessment programme A modelled analysis using data from the ARTISTIC trial of the potential effectiveness and cost-effectiveness of HPV testing in cervical cancer screening
2014 Malaysian Health Technology Assessment (MaHTAS) OncoE6TM cervical screening test kit
2013 National Evidence-based Healthcare Collaborating Agency (NECA) [Cost-effectiveness of human papillomavirus vaccination in South Korea]
2013 Andalusian Health Technology Assessment Area (AETSA) [Efficacy, effectivity and efficiency of liquid cytology for cervical cancer screening and HPV infection diagnosis]
2012 HAYES, Inc. Human papillomavirus (HPV) genotyping to test for the presence of HPV 16 and 18 in women
2012 NIHR Horizon Scanning Centre (NIHR HSC) HPV OncoTect® E6 E7 mRNA Assay to guide colposcopy referral in cervical cancer screening
2012 Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of human papillomavirus (HPV) testing, followed by liquid-based cytology triage of positive results, in primary screening for cervical cancer?
2012 Scottish Health Technologies Group (SHTG) High-risk human papillomavirus (HPV) testing as triage for women with mild or borderline cytology abnormalities
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care: Standards on how to parameterise models via published literature: Input of the LBI-HTA (WP 4.2)
2012 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Economic evaluation of the introduction of the HPV vaccine in Spain to prevent cervical cancer]
2011 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Benefit assessment of HPV testing in primary screening for cervical cancer]
2011 Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) HPV DNA-based screening test for cervical cancer
2011 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benefit assessment of HPV test in primary screening for cervical cancer]
2010 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Detection of high risk human papillomavirus E6 and E7 oncogenes for cervical cancer screening]
2010 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany]
2010 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Information to users on cancer screening in women: assessment of current situation and establishment of evidence-based information standards 2. Information to users on cervical cancer screening]
2009 Institute of Health Economics (IHE) Human papillomavirus (HPV) testing in Alberta
2009 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Developing a decision aid on HPV-vaccination for young girls and women/ mothers
2009 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors]
2009 Institute of Health Economics (IHE) Human papillomavirus (HPV) testing in Alberta
2009 Adelaide Health Technology Assessment (AHTA) Cervista HPV 16/18 for the identification of strains of the human papillomavirus associated with cervical cancer
2009 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Development of decision-aid: HPV-patient information]
2009 NIHR Health Technology Assessment programme ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening
2008 Canadian Agency for Drugs and Technologies in Health (CADTH) Liquid-based techniques for cervical cancer screening: systematic review and cost-effectiveness analysis
2008 Norwegian Knowledge Centre for the Health Services (NOKC) [HPV RNA test for cervical cancer]
2008 Committee for New Health Technology Assessment (CNHTA) [HPV genotype(PCR-RFMP)]
2008 The Swedish Council on Health Technology Assessment (SBU) [General childhood vaccination against HPV 16 and 18 aimed at preventing cervical cancer]
2008 Health Intervention and Technology Assessment Program (HITAP) Research for development of an optimal policy strategy for prevention and control of Cervical Cancer in Thailand
2008 Technology Assessment Unit of the McGill University Health Centre (MUHC) Adoption of liquid-based cytology: technological evaluation
2007 New Zealand Health Technology Assessment (NZHTA) Performance of commercially available HPV tests
2007 Medical Advisory Secretariat (MAS) Anal dysplasia screening: an evidence-based analysis
2007 Adelaide Health Technology Assessment (AHTA) Tam Pap for self testing of HPV
2007 Belgian Health Care Knowledge Centre (KCE) HPV vaccination for the prevention of cervical cancer in Belgium
2007 Canadian Agency for Drugs and Technologies in Health (CADTH) Human papillomavirus (HPV) vaccines: A Canadian update
2007 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Economic evaluation of HPV vaccination in Austria
2007 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment]
2007 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical cancer]
2006 HAYES, Inc. Human papillomavirus vaccines for prevention of cervical cancer
2006 Institute for Clinical Effectiveness and Health Policy (IECS) Efficacy of the human papillomavirus (HPV) vaccine
2006 HAYES, Inc. Human papillomavirus vaccines for prevention of cervical cancer
2006 Belgian Health Care Knowledge Centre (KCE) Cervical cancer screening and Human Papillomavirus (HPV) testing
2005 Institute for Clinical Systems Improvement (ICSI) HPV DNA testing for the screening and monitoring of cervical cancer
2005 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [The use of liquid based cytology (LBC) and conventional pap smear (CPS) for cervical screening in Denmark]
2005 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for prevention of human papillomavirus infection
2004 L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Assessment of human papilloma virus (HPV) testing in primary screening for cervical cancer in France
2004 HAYES, Inc. Hybrid capture HPV testing for cervical cancer
2004 Medical Services Advisory Committee (MSAC) The use of human papillomavirus testing to monitor effectiveness of treatment of high-grade intraepithelial abnormalities of the cervix
2003 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Liquid-based cytology and human papillomavirus testing in cervical cancer screening
2003 Medical Services Advisory Committee (MSAC) Human papillomavirus testing for cervical screening
2003 Institute for Clinical Systems Improvement (ICSI) Liquid-based cervical cytology
2002 Health Technology Advisory Committee (HTAC) Screening for cervical cancer: recent advances
2002 Agency for Healthcare Research and Quality (AHRQ) Screening for cervical cancer
2001 Institute for Clinical Systems Improvement (ICSI) HPV DNA testing for cervical cancer
1999 NIHR Health Technology Assessment programme A systematic review of the role of human papillomavirus testing within a cervical screening programme